Expanding Approved Patient Populations for Rare Disease Treatment Using In Vitro Data. Issue 1 (3rd October 2021)

• Record Type: Journal Article
• Authors: Weaver, James L.; Wu, Wendy; Hyland, Paula L.; Lim, Robert; Smpokou, Patroula; Pacanowski, Michael
• Is Part Of: Clinical pharmacology & therapeutics. Volume 112:Issue 1(2022)
• Page Start: 58
• Page End: 61
• Publication Date: 2021-10-03
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2414
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : In vitro cell‐based data can be used to support the extension of pharmaceutical approval to patient subsets with unique genetic variants. A set of conditions should be satisfied to support the extension of approval. The disease mechanism should be well described, and the impact of variants on protein function should be reasonably understood. The incidence data should show that clinical trials for the variants in question are not practical. The overall safety and efficacy of the drug should be clear in adequate and well‐controlled clinical trials. The clinical trial should include patients found to be responders and nonresponders so that both positive and negative predictive power of the in vitro assay may be measured. The mechanism of action of the drug should be clearly defined and should be consistent with the disease mechanism. The assay system should be qualified, including the following points: (i) each variant construct should be confirmed by bidirectional sequencing; (ii) the in vitro assay should directly measure the variant protein function in comparison with the reference protein; (iii) the assay should be formally validated to the extent possible, clearly demonstrating precision, reproducibility, and sensitivity used to support the efficacy claim; and (iv) the primary data should be available for inspection and analytical validation. The overall goal is a robust and validated cell‐based system that can be shown to predict the outcome of targeted therapy.